Monopar Therapeutics Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 3 - Cash Equivalents and Investments

Note 3 - Cash Equivalents and Investments

12 Months Ended

Dec. 31, 2025

Cash, Cash Equivalent, and Short-Term Investment [Text Block]

Note 3 – Cash Equivalents and Investments

As of December 31, 2025, the Company had money market accounts and available-for-sale investments with contractual maturities of three months or less categorized as cash equivalents as follows:

As of December 31, 2025	*Cost Basis*		*Unrealized Gains*		*Aggregate Fair Value*

U.S. Treasury Securities	$	12,730,543	$	25,314	$	12,755,857
Commercial Paper		41,703,814		132,003		41,835,818
Money Market Accounts		6,284,294		—		6,284,294
Total	$	60,718,652	$	157,317	$	60,875,969

As of December 31, 2025, there were no available-for-sale securities in an unrealized-loss position.

As of December 31, 2024, the Company had money market accounts and available-for-sale investments with contractual maturities of three months or less categorized as cash equivalents as follows:

As of December 31, 2024	*Cost Basis*		*Unrealized Gains*		*Aggregate Fair Value*

U.S. Treasury Securities	$	40,969,665	$	57,731	$	41,027,396
Money Market Accounts		4,504,250		—		4,504,250
Total	$	45,473,915	$	57,731	$	45,531,646

As of December 31, 2024, there were no available-for-sale securities in an unrealized-loss position.

As of December 31, 2025 and 2024, the Company had held-to-maturity investments with contractual maturities of over three months to one year. These investments are reported as held-to-maturity because the Company has both the positive intent and ability to hold these investments to maturity; they are stated at amortized cost, adjusted for the amortization of any related premiums or the accretion of any related discounts into interest income.

The held-to-maturity investments are reported in the consolidated balance sheet as of December 31, 2025, and consist of the following:

As of December 31, 2025	*Amortized Cost*		*Unrealized Gains*		*Unrealized Losses*			*Fair Market Value*

U.S. Treasury Securities	$	30,147,733	$	18,931	$	—		$	30,166,664
Commercial Paper		48,417,758		3,616		(2,284	)		48,419,090
Total	$	78,565,491	$	22,547	$	(2,284	)	$	78,585,754

As of December 31, 2025, gross unrealized gains and unrealized losses for held-to-maturity securities were $22,547 and $2,284, respectively. The Company has determined that these gross unrealized losses of $2,284 are primarily attributable to fluctuations in market interest rates rather than credit-related factors. The Company’s commercial paper and U.S. Treasury holdings consist of high-credit-quality issuers and government-backed securities, respectively. The Company evaluated its held-to-maturity securities for expected credit losses and determined that any such losses would be immaterial. This assessment is based on the high credit quality of the issuers, the short-term nature of the instruments, and the Company’s intent and ability to hold these investments until maturity. Accordingly, no allowance for credit losses was recorded as of December 31, 2025.

The held-to-maturity investments are reported in the consolidated balance sheet as of December 31, 2024, and consist of the following:

As of December 31, 2024	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Market Value

U.S. Treasury Securities	$	14,395,913	$	10,863	$	—	$	14,406,776
Total	$	14,395,913	$	10,863	$	—	$	14,406,776

As of December 31, 2024, there were no held-to-maturity securities in an unrealized-loss position.

See Note 2 for additional discussion regarding the Company’s fair value measurements.